Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
South Africa
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Epoprostanol
2. Epoprostenol
3. Epoprostenol Sodium Salt, (5z,9alpha,11alpha,13e,15s)-isomer
4. Flolan
5. Prostacyclin
6. Prostaglandin I(2)
7. Prostaglandin I2
8. Veletri
1. Flolan
2. Epoprostenol
3. Prostacyclin Sodium Salt
4. 61849-14-7
5. Sodium Prostacyclin
6. Prostaglandin I2
7. U-53217a
8. U-53,217a
9. 4k04iq1of4
10. Cyclo-prostin
11. 35121-78-9
12. Epoprostenol Sodium [usan:ban]
13. Ncgc00167427-01
14. Einecs 263-273-7
15. Unii-4k04iq1of4
16. Floran
17. U 53,217a
18. Epoprostenolsodium
19. Prostacyclin Sodium
20. Prostaglandin X Sodium
21. Prostaglandin I2 Na
22. Chembl962
23. Dsstox_cid_26617
24. Dsstox_rid_81769
25. Sodium (5z,13e,15s)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dien-1-oate
26. Dsstox_gsid_46617
27. Schembl41344
28. Sodium (z)-(3ar,4r,5r,6as)-hexahydro-5-hydroxy-4-((e)-(3s)-3-hydroxy-1-octenyl)-2h-cyclopenta(b)furan-delta(sup 2,delta)-valerate
29. Bml1-f10
30. Dtxsid3046617
31. Epoprostenol Sodium [jan]
32. 4ua76
33. Epoprostenol Sodium [usan]
34. Hms1361k18
35. Hms3648l14
36. Epoprostenol Sodium [vandf]
37. Epoprostenol Sodium [mart.]
38. Tox21_112431
39. Epoprostenol Sodium [usp-rs]
40. Epoprostenol Sodium [who-dd]
41. Prostacyclin Sodium Salt [mi]
42. Akos024457370
43. Epoprostenol Sodium [orange Book]
44. Prosta-5,13-dien-1-oic Acid, 6,9-epoxy-11,15-dihydroxy-, Sodium Salt, (5z,9alpha,11alpha,13e,15s)-
45. Cas-61849-14-7
46. Q27259818
47. (5z,13e,8r,9s,11r,12r,15s)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic Acid Sodium Salt
48. Prosta-5,13-dien-1-oic Acid, 6,9-epoxy-11,15-dihydroxy-, Sodium Salt, (5z,9.alpha.,11.alpha.,13e,15s)-
49. Sodium (z)-(3ar,4r,5r,6as)-hexahydro-5-hydroxy-4-((e)-(3s)-3-hydroxy-1-octenyl)-2h-cyclopenta(b)furan-.delta.(sup 2,.delta.)-valerate
50. Sodium (z)-5-((3ar,4r,5r,6as)-5-hydroxy-4-((s,e)-3-hydroxyoct-1-enyl)hexahydro-2h-cyclopenta[b]furan-2-ylidene)pentanoate
Molecular Weight | 374.4 g/mol |
---|---|
Molecular Formula | C20H31NaO5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 10 |
Exact Mass | 374.20691837 g/mol |
Monoisotopic Mass | 374.20691837 g/mol |
Topological Polar Surface Area | 89.8 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 491 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Epoprostenol sodium |
PubMed Health | Epoprostenol (Injection) |
Drug Classes | Peripheral Vasodilator, Platelet Aggregation Inhibitor |
Drug Label | Epoprostenol sodium for injection is a sterile sodium salt formulated for intravenous (IV) administration. Each vial of epoprostenol sodium for injection contains epoprostenol sodium equivalent to either 0.5 mg (500,000 ng) or 1.5 mg (1,500,000 ng) e... |
Active Ingredient | Epoprostenol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 1.5mg base/vial; eq 0.5mg base/vial |
Market Status | Prescription |
Company | Teva Pharms Usa |
2 of 4 | |
---|---|
Drug Name | Flolan |
Drug Label | FLOLAN (epoprostenol sodium) for Injection is a sterile sodium salt formulated for intravenous (IV) administration. Each vial of FLOLAN contains epoprostenol sodium equivalent to either 0.5mg (500,000ng) or 1.5mg (1,500,000ng) epoprostenol, 3... |
Active Ingredient | Epoprostenol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 1.5mg base/vial; eq 0.5mg base/vial |
Market Status | Prescription |
Company | Glaxosmithkline |
3 of 4 | |
---|---|
Drug Name | Epoprostenol sodium |
PubMed Health | Epoprostenol (Injection) |
Drug Classes | Peripheral Vasodilator, Platelet Aggregation Inhibitor |
Drug Label | Epoprostenol sodium for injection is a sterile sodium salt formulated for intravenous (IV) administration. Each vial of epoprostenol sodium for injection contains epoprostenol sodium equivalent to either 0.5 mg (500,000 ng) or 1.5 mg (1,500,000 ng) e... |
Active Ingredient | Epoprostenol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 1.5mg base/vial; eq 0.5mg base/vial |
Market Status | Prescription |
Company | Teva Pharms Usa |
4 of 4 | |
---|---|
Drug Name | Flolan |
Drug Label | FLOLAN (epoprostenol sodium) for Injection is a sterile sodium salt formulated for intravenous (IV) administration. Each vial of FLOLAN contains epoprostenol sodium equivalent to either 0.5mg (500,000ng) or 1.5mg (1,500,000ng) epoprostenol, 3... |
Active Ingredient | Epoprostenol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 1.5mg base/vial; eq 0.5mg base/vial |
Market Status | Prescription |
Company | Glaxosmithkline |
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
B - Blood and blood forming organs
B01 - Antithrombotic agents
B01A - Antithrombotic agents
B01AC - Platelet aggregation inhibitors excl. heparin
B01AC09 - Epoprostenol
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Epoprostenol Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Epoprostenol Sodium, including repackagers and relabelers. The FDA regulates Epoprostenol Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Epoprostenol Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Epoprostenol Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Epoprostenol Sodium supplier is an individual or a company that provides Epoprostenol Sodium active pharmaceutical ingredient (API) or Epoprostenol Sodium finished formulations upon request. The Epoprostenol Sodium suppliers may include Epoprostenol Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Epoprostenol Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Epoprostenol Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Epoprostenol Sodium active pharmaceutical ingredient (API) in detail. Different forms of Epoprostenol Sodium DMFs exist exist since differing nations have different regulations, such as Epoprostenol Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Epoprostenol Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Epoprostenol Sodium USDMF includes data on Epoprostenol Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Epoprostenol Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Epoprostenol Sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Epoprostenol Sodium Drug Master File in Japan (Epoprostenol Sodium JDMF) empowers Epoprostenol Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Epoprostenol Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Epoprostenol Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Epoprostenol Sodium suppliers with JDMF on PharmaCompass.
A Epoprostenol Sodium written confirmation (Epoprostenol Sodium WC) is an official document issued by a regulatory agency to a Epoprostenol Sodium manufacturer, verifying that the manufacturing facility of a Epoprostenol Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Epoprostenol Sodium APIs or Epoprostenol Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Epoprostenol Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Epoprostenol Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Epoprostenol Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Epoprostenol Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Epoprostenol Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Epoprostenol Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Epoprostenol Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Epoprostenol Sodium suppliers with NDC on PharmaCompass.
Epoprostenol Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Epoprostenol Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Epoprostenol Sodium GMP manufacturer or Epoprostenol Sodium GMP API supplier for your needs.
A Epoprostenol Sodium CoA (Certificate of Analysis) is a formal document that attests to Epoprostenol Sodium's compliance with Epoprostenol Sodium specifications and serves as a tool for batch-level quality control.
Epoprostenol Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Epoprostenol Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Epoprostenol Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Epoprostenol Sodium EP), Epoprostenol Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Epoprostenol Sodium USP).
LOOKING FOR A SUPPLIER?